title: Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II.
abstract: Dopamine produced by renal proximal tubules increases sodium excretion via a decrease in renal sodium reabsorption. Dopamine natriuresis is impaired in obese Zucker rats; however, the mechanism is not fully understood. To test the hypothesis that renal expression of one or more of the subtypes are altered in these rats, we measured whole kidney protein levels by immunoblotting of D1-like (D1R and D5R) and D2-like (D2R, D3R, and D4R) dopamine receptors in both male and female obese and lean Zucker rats. In obese males on 1% NaCl diet, D1R, D2R, D4R, and D5R were decreased, while D3R was increased, relative to lean rats. Under a 4% NaCl diet, D2R and D3R levels in obese rats were restored to lean levels. 4% NaCl diet reduced D5R in both body types, relative to 1% NaCl diet. Female rats had higher expression of D1R and D3R than did male; however, the sex difference for D1R was markedly blunted in obese rats. In obese rats, dietary candesartan (angiotensin II type 1 receptor blocker) normalized downregulated D1R and D2R, but either decreased (D3R), did not affect (D4R), or further downregulated (D5R) the other subtypes. Candesartan also decreased D4R in lean rats. In summary, reduced renal protein levels of D1R, D2R, D4R, and D5R in obese Zucker rats could induce salt sensitivity and elevate blood pressure. Increased angiotensin II type 1 receptor activity may be mechanistically involved in the decreased expression of D1R and D2R in obese rats. Finally, reduced D1R and D3R in male rats may contribute to sex differences in blood pressure.
authors.affiliation: Bldg D, Rm 392, Georgetown Univ., 4000 Reservoir Rd NW, Washington, DC 20007, USA.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Wang
authors.forename: Fengmin
authors.initials: F
authors.lastname: Li
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Jose
authors.forename: Carolyn M
authors.initials: CM
authors.lastname: Ecelbarger
mesh_terms: D000804:Angiotensin II / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D015153:Blotting, Western; D001823:Body Composition / Q000502:physiology; D004032:Diet; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009765:Obesity / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D011954:Receptors, Dopamine / Q000096:biosynthesis*; D012727:Sex Characteristics; D017673:Sodium Chloride, Dietary / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011954:Receptors, Dopamine; D017673:Sodium Chloride, Dietary; D013777:Tetrazoles; D000804:Angiotensin II; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; C081643:candesartan
references.citation: J Clin Invest. 1996 May 15;97(10):2283-8
references.pmid: 8636408
references.citation: Kidney Int. 2004 Dec;66(6):2167-80
references.pmid: 15569306
references.citation: J Clin Invest. 1998 Aug 1;102(3):493-8
references.pmid: 9691085
references.citation: Am J Physiol. 1992 Sep;263(3 Pt 2):R631-8
references.pmid: 1357983
references.citation: Hypertension. 2005 Apr;45(4):804-10
references.pmid: 15699451
references.citation: Neuroimage. 2008 Oct 1;42(4):1537-43
references.pmid: 18598772
references.citation: Hypertension. 1990 Jun;15(6 Pt 1):560-9
references.pmid: 1971811
references.citation: Clin Exp Hypertens. 2001 Nov;23(8):591-601
references.pmid: 11728004
references.citation: Curr Hypertens Rep. 2008 Aug;10(4):268-75
references.pmid: 18625155
references.citation: Hypertension. 1999 Nov;34(5):1091-6
references.pmid: 10567187
references.citation: Lab Invest. 2006 Mar;86(3):262-74
references.pmid: 16402031
references.citation: Clin Sci (Lond). 1988 Dec;75(6):569-75
references.pmid: 2974769
references.citation: Behav Brain Res. 2004 May 5;151(1-2):313-9
references.pmid: 15084447
references.citation: Am J Physiol. 1989 Sep;257(3 Pt 2):F469-77
references.pmid: 2528916
references.citation: Nutr Neurosci. 2002 Oct;5(5):321-6
references.pmid: 12385594
references.citation: Hypertension. 2003 Jun;41(6):1353-8
references.pmid: 12707290
references.citation: Brain Res Bull. 2008 Jan 31;75(1):70-6
references.pmid: 18158098
references.citation: Clin Exp Hypertens. 2003 Nov;25(8):509-15
references.pmid: 14649308
references.citation: J Neurosci. 2002 Dec 15;22(24):10801-10
references.pmid: 12486173
references.citation: Am J Clin Nutr. 1992 Nov;56(5):827-34
references.pmid: 1415000
references.citation: JAMA. 2002 Jan 16;287(3):356-9
references.pmid: 11790215
references.citation: FASEB J. 2008 Aug;22(8):2740-6
references.pmid: 18477764
references.citation: Hypertension. 1999 Apr;33(4):1036-42
references.pmid: 10205244
references.citation: Obes Res. 1993 Jan;1(1):5-17
references.pmid: 16353346
references.citation: Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R96-R104
references.pmid: 16352863
references.citation: Am J Physiol Renal Physiol. 2004 Jul;287(1):F109-16
references.pmid: 15068975
references.citation: Aviat Space Environ Med. 1996 Mar;67(3):248-52
references.pmid: 8775403
references.citation: Clin Exp Hypertens. 2000 Aug;22(6):635-44
references.pmid: 10972167
references.citation: Hypertension. 2002 Dec;40(6):880-5
references.pmid: 12468573
references.citation: Am J Physiol Renal Physiol. 2008 May;294(5):F1222-31
references.pmid: 18305093
references.citation: J Hum Hypertens. 2002 Mar;16 Suppl 1:S13-7
references.pmid: 11986886
references.citation: Gend Med. 2007 Sep;4(3):214-29
references.pmid: 18022589
references.citation: Neuroendocrinology. 2009;89(2):152-62
references.pmid: 18984941
references.citation: Eur J Pharmacol. 2003 Nov 7;480(1-3):125-31
references.pmid: 14623356
references.citation: Am J Physiol. 1998 Oct;275(4):R986-94
references.pmid: 9756526
references.citation: Clin Exp Hypertens A. 1992;14(4):615-28
references.pmid: 1352742
references.citation: Am J Hypertens. 1988 Jan;1(1):31-7
references.pmid: 3285858
references.citation: Handb Exp Pharmacol. 2005;(170):107-33
references.pmid: 16596797
references.citation: Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1071-8
references.pmid: 11557612
references.citation: Circulation. 2005 Apr 19;111(15):1962-9
references.pmid: 15837950
references.citation: Pediatr Nephrol. 2008 Dec;23(12):2131-46
references.pmid: 18615257
references.citation: Hypertension. 2000 Jan;35(1 Pt 2):403-8
references.pmid: 10642332
references.citation: J Clin Invest. 2008 Jun;118(6):2180-9
references.pmid: 18464932
references.citation: Diabetes. 2005 Jul;54(7):2219-26
references.pmid: 15983225
references.citation: Hypertens Res. 2007 Jan;30(1):93-101
references.pmid: 17460376
references.citation: Am J Physiol Renal Physiol. 2000 Jul;279(1):F46-53
references.pmid: 10894786
references.citation: Clin Exp Hypertens. 2009 Feb;31(1):49-63
references.pmid: 19172459